SE460967B - Ergolinderivat, saett att framstaella dessa och en farmaceutisk komposition med antihypertensiv och antiprolaktinisk verkan - Google Patents
Ergolinderivat, saett att framstaella dessa och en farmaceutisk komposition med antihypertensiv och antiprolaktinisk verkanInfo
- Publication number
- SE460967B SE460967B SE8302379A SE8302379A SE460967B SE 460967 B SE460967 B SE 460967B SE 8302379 A SE8302379 A SE 8302379A SE 8302379 A SE8302379 A SE 8302379A SE 460967 B SE460967 B SE 460967B
- Authority
- SE
- Sweden
- Prior art keywords
- ergoline
- group
- dimethyl
- methyl
- carbon atoms
- Prior art date
Links
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 title claims description 11
- 230000003276 anti-hypertensive effect Effects 0.000 title claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 230000000694 effects Effects 0.000 title description 6
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 15
- -1 3,5-dimethyl-4-pyrazolylmethyl Chemical group 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 claims 2
- UVRKPZFZUNTZRE-BSLALVQMSA-N C(CC)N1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C34)CC=3C(=NNC3C)C Chemical compound C(CC)N1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C34)CC=3C(=NNC3C)C UVRKPZFZUNTZRE-BSLALVQMSA-N 0.000 claims 1
- INPUGVRLJYCZLC-WONHAXNMSA-N CC1=C(C(=NC(=N1)N)C)C[C@@H]2C[C@]3([C@@H](CC4=CN(C5=CC=CC3=C45)C)N(C2)C)OC Chemical compound CC1=C(C(=NC(=N1)N)C)C[C@@H]2C[C@]3([C@@H](CC4=CN(C5=CC=CC3=C45)C)N(C2)C)OC INPUGVRLJYCZLC-WONHAXNMSA-N 0.000 claims 1
- NPUOHVICJAPTFV-BSDZUQITSA-N CC1=C(C(=NN1C)C)C[C@@H]2C[C@]3([C@@H](CC4=CN(C5=CC=CC3=C45)C)N(C2)C)OC Chemical compound CC1=C(C(=NN1C)C)C[C@@H]2C[C@]3([C@@H](CC4=CN(C5=CC=CC3=C45)C)N(C2)C)OC NPUOHVICJAPTFV-BSDZUQITSA-N 0.000 claims 1
- CVAKIMWSYKNKQG-BSLALVQMSA-N CN1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CC=1C(=NC(=NC=1C)N(C)C)C Chemical compound CN1C[C@@H](C[C@@H]2C=3C=CC=C4NC=C(C[C@@H]12)C=34)CC=1C(=NC(=NC=1C)N(C)C)C CVAKIMWSYKNKQG-BSLALVQMSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 description 12
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 7
- 229960002474 hydralazine Drugs 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N 1,1-dimethylguanidine Chemical compound CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- YKCQWHAETAVJDG-LXGCGDOSSA-N 3-[[(6ar,9s,10ar)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methyl]pentane-2,4-dione Chemical compound C1=CC([C@H]2C[C@@H](CC(C(C)=O)C(C)=O)CN([C@@H]2C2)C)=C3C2=CNC3=C1 YKCQWHAETAVJDG-LXGCGDOSSA-N 0.000 description 2
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- XKQGTVLROWPFTC-LXGCGDOSSA-N (6ar,9s,10ar)-9-[(3,5-dimethyl-1h-pyrazol-4-yl)methyl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C=1C(C)=NNC=1C XKQGTVLROWPFTC-LXGCGDOSSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- STIAPHVBRDNOAJ-UHFFFAOYSA-N carbamimidoylazanium;carbonate Chemical compound NC(N)=N.NC(N)=N.OC(O)=O STIAPHVBRDNOAJ-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8212653 | 1982-04-30 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8302379D0 SE8302379D0 (sv) | 1983-04-27 |
| SE8302379L SE8302379L (sv) | 1983-10-31 |
| SE460967B true SE460967B (sv) | 1989-12-11 |
Family
ID=10530108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8302379A SE460967B (sv) | 1982-04-30 | 1983-04-27 | Ergolinderivat, saett att framstaella dessa och en farmaceutisk komposition med antihypertensiv och antiprolaktinisk verkan |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US4657914A (en]) |
| JP (1) | JPS58194884A (en]) |
| AT (1) | AT385035B (en]) |
| AU (1) | AU553851B2 (en]) |
| BE (1) | BE896609A (en]) |
| CA (1) | CA1210389A (en]) |
| CH (1) | CH654305A5 (en]) |
| CS (1) | CS236874B2 (en]) |
| DE (1) | DE3314878A1 (en]) |
| DK (1) | DK164058C (en]) |
| FI (1) | FI73996C (en]) |
| FR (1) | FR2526022B1 (en]) |
| GB (1) | GB2120242A (en]) |
| GR (1) | GR78842B (en]) |
| HU (1) | HU193527B (en]) |
| IE (1) | IE53950B1 (en]) |
| IL (1) | IL68496A (en]) |
| IT (1) | IT1215630B (en]) |
| NL (1) | NL191709C (en]) |
| SE (1) | SE460967B (en]) |
| ZA (1) | ZA833008B (en]) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8714767D0 (en) * | 1987-06-24 | 1987-07-29 | Erba Farmitalia | Egoline derivatives |
| HU190105B (en) * | 1983-06-03 | 1986-08-28 | Gyogyszerkutato Intezet | Process for production of pirazolyl-methyl-ergolin- derivatives and their acid additional salts |
| GB2173189B (en) * | 1985-02-21 | 1988-04-27 | Maruko Pharmaceutical Co | Ergoline derivatives and salts thereof and pharmaceutical compositions thereof |
| GB8702364D0 (en) * | 1987-02-03 | 1987-03-11 | Erba Farmitalia | Ergolinyl heterocycles |
| EP2566333A4 (en) | 2010-05-07 | 2014-04-02 | Univ Leland Stanford Junior | IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS |
| US20160045609A1 (en) | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
| CN110381940B (zh) | 2017-02-17 | 2023-07-21 | 文涵治疗有限公司 | Ag-10的制备方法、其中间体及其盐 |
| SG11202009073WA (en) | 2018-03-23 | 2020-10-29 | Eidos Therapeutics Inc | Methods of treating ttr amyloidosis using ag10 |
| EP3836920A4 (en) | 2018-08-17 | 2022-04-13 | Eidos Therapeutics, Inc. | AG10 FORMULAS |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3238211A (en) * | 1966-03-01 | Derhvatives of g-methyl and i,g-dimethyl ergolhne | ||
| US3296071A (en) * | 1963-05-31 | 1967-01-03 | Upjohn Co | Reducing blood sugar with 3-alkyl-5-alkoxymethylisoxazole |
| BE712054A (en]) * | 1967-03-16 | 1968-07-15 | ||
| US3957785A (en) * | 1971-12-02 | 1976-05-18 | Societa' Farmaceutici Italia S.P.A. | Bβ-Pyrimidino-aminomethyl-10α-ergoline and 10α-methoxyergoline derivatives |
| CH563376A5 (en]) * | 1972-06-29 | 1975-06-30 | Lonza Ag | |
| US3996228A (en) * | 1973-12-21 | 1976-12-07 | Societa' Farmaceutici Italia S.P.A. | Pyrimidinoaminoethyl ergoline derivatives |
| NL7416120A (nl) * | 1973-12-21 | 1975-06-24 | Farmaceutici Italia | Werkwijze voor het bereiden van pyrimidinoami- nomethylergolinederivaten. |
| IE41533B1 (en) * | 1974-03-14 | 1980-01-30 | Sandoz Ltd | Thiomethyl ergolene derivatives |
| US4147789A (en) * | 1974-03-14 | 1979-04-03 | Sandoz Ltd. | 6-Methyl-8-thiomethyl-ergolene derivatives |
| CS171480B1 (en]) * | 1974-03-19 | 1976-10-29 | ||
| CS177530B1 (en) * | 1974-07-19 | 1977-07-29 | Miroslav Semonsky | New nbeta-substituted derivatives of b-beta-aminoethyl-ergoline-i their salts and methods for the production thereof |
| CH617452A5 (en]) * | 1974-10-25 | 1980-05-30 | Hoffmann La Roche | |
| CH615929A5 (en) * | 1975-06-02 | 1980-02-29 | Sandoz Ag | Process for the preparation of novel ergoline compounds |
| CH622518A5 (en) * | 1976-12-14 | 1981-04-15 | Sandoz Ag | Process for the preparation of novel ergoline compounds |
| AU526764B2 (en) * | 1978-09-08 | 1983-01-27 | Farmitalia Carlo Erba S.P.A. | Ergoline derivatives |
| GB2056437A (en) * | 1979-08-07 | 1981-03-18 | Erba Farmitalia | Secoergoline derivatives |
| US4382940A (en) * | 1979-12-06 | 1983-05-10 | Farmitalia Carlo Erba S.P.A. | Ercoline derivatives and therapeutic compositions having CNS affecting activity |
-
1983
- 1983-04-21 GB GB08310843A patent/GB2120242A/en not_active Withdrawn
- 1983-04-25 FI FI831406A patent/FI73996C/fi not_active IP Right Cessation
- 1983-04-25 DE DE19833314878 patent/DE3314878A1/de active Granted
- 1983-04-25 IE IE932/83A patent/IE53950B1/en not_active IP Right Cessation
- 1983-04-25 GR GR71190A patent/GR78842B/el unknown
- 1983-04-25 CS CS832921A patent/CS236874B2/cs unknown
- 1983-04-25 US US06/488,168 patent/US4657914A/en not_active Expired - Fee Related
- 1983-04-26 CH CH2256/83A patent/CH654305A5/it not_active IP Right Cessation
- 1983-04-26 JP JP58072295A patent/JPS58194884A/ja active Granted
- 1983-04-26 IL IL68496A patent/IL68496A/xx not_active IP Right Cessation
- 1983-04-27 CA CA000426874A patent/CA1210389A/en not_active Expired
- 1983-04-27 SE SE8302379A patent/SE460967B/sv not_active IP Right Cessation
- 1983-04-27 IT IT8320807A patent/IT1215630B/it active
- 1983-04-27 FR FR8306926A patent/FR2526022B1/fr not_active Expired
- 1983-04-27 HU HU851631A patent/HU193527B/hu not_active IP Right Cessation
- 1983-04-28 ZA ZA833008A patent/ZA833008B/xx unknown
- 1983-04-28 DK DK189983A patent/DK164058C/da not_active IP Right Cessation
- 1983-04-28 AU AU14029/83A patent/AU553851B2/en not_active Ceased
- 1983-04-29 BE BE0/210660A patent/BE896609A/fr not_active IP Right Cessation
- 1983-04-29 AT AT0156783A patent/AT385035B/de not_active IP Right Cessation
- 1983-04-29 NL NL8301529A patent/NL191709C/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1436872A3 (ru) | Способ получени производных пиримидина | |
| US4675321A (en) | Substituted pyrimidines useful as calcium channel blockers | |
| US3773956A (en) | Azido-aryl 1,4-dihydropyridines in effecting coronary dilation | |
| ES2649475T3 (es) | Derivados de piridin-4-ilo | |
| JP2001520645A (ja) | 新規な化合物 | |
| FR2673427A1 (fr) | Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. | |
| US4690929A (en) | Ergolines exhibiting protactin secretion inhibition activity | |
| SE460967B (sv) | Ergolinderivat, saett att framstaella dessa och en farmaceutisk komposition med antihypertensiv och antiprolaktinisk verkan | |
| CA2077967A1 (en) | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present | |
| SK281467B6 (sk) | Krátko pôsobiace dihydropyridíny, spôsoby ich prípravy, farmaceutické prípravky s ich obsahom a ich použitie | |
| HU201955B (en) | Process for producing new ribofuranuronic acid derivatives and pharmaceutical compositions comprising such compounds | |
| HU212133B (en) | Therapeutic agents | |
| JPH0226629B2 (en]) | ||
| EP1100786B1 (en) | Antiviral pyrimidinedione derivatives and process for the preparation thereof | |
| US4087526A (en) | (3-Amino-5-substituted-6-fluoropyrazinoyl or pyrazamido)-guanidines and their derivatives bearing substituents on the guanidino nitrogens | |
| SK170183A3 (en) | Theophyline derivatives, substituted in position 7 and method of their production | |
| US4238490A (en) | Antihypertensive pyridazin(2H)-3-ones | |
| HU179450B (en) | Process for producing ergoline derivatives | |
| JP3160941B2 (ja) | カルバゾール誘導体および免疫抑制剤 | |
| EP0936911B1 (en) | Adenosine deaminase inhibitors | |
| SU1731049A3 (ru) | Способ получени симметричного эфира 4-замещенной 1,4-дигидропиридин-3,5-дикарбоновой кислоты или его физиологически приемлемых солей | |
| JPH0578554B2 (en]) | ||
| NO913644L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater. | |
| EP0292981B1 (en) | 2-selenomethyl-1, 4-dihydropyridines, a process for the preparation thereof and pharmaceutical compositions containing them | |
| US4004009A (en) | Antihypertensive aryl pyrazolo[4,3-c]pyridazinones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8302379-6 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8302379-6 Format of ref document f/p: F |